{
  "docId": "019de072-0f48-75dc-8e26-6c36719c246a",
  "docSlug": "59aa3600901f9a5fdbc1ca4ce261b5cc",
  "documentTitle": "Vigil Neuroscience | IPO Presentation Deck | 54 slides",
  "authorId": "vigil-neuroscience",
  "authorName": "Vigil Neuroscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 17,
  "pageCount": 54,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a honeycomb-style layout to present five key product attributes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0f48-75dc-8e26-6c36719c246a/17",
  "deckHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a",
  "deckJsonHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a.json",
  "deckAnchorHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.05,
        "y": 0.425
      },
      "kind": "diagram",
      "text": "Human monoclonal antibody highly selective for TREM2",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13ecf865-0213-495a-a951-e5cf7affa87d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.75,
        "y": 0.425
      },
      "kind": "diagram",
      "text": "Strong IP position",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "617f601b-cb1f-4366-90c3-97d897125e3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.4,
        "y": 0.425
      },
      "kind": "diagram",
      "text": "Compelling in vitro & in vivo data",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e0beca3-cf24-419d-93a4-56f77ca8e34c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.22,
        "y": 0.26
      },
      "kind": "diagram",
      "text": "Sub-nanomolar potency in human cells",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92d2402e-6aed-4f0e-8b43-b88f5b8056d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.58,
        "y": 0.26
      },
      "kind": "diagram",
      "text": "Established manufacturing competency",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "988dfbcb-1771-4cbe-bd2f-99d2117bfef0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "VGL101 – Antibody Agonist of TREM2 with a Compelling Profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06574043-81cc-4150-8c98-d5cd5321db81",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "8de61beb-c317-405f-998a-6d38b255896f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents VGL101 as a potential solution for neurodegenerative diseases and provides data on its efficacy and safety.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}